GlaxoSmithKline (GSK) Pharmaceuticals suffered a 63 per cent decline in net profit in the last quarter as implementation of the goods and services tax (GST) led to de-stocking. Annaswamy Vaidheesh, managing director of the British drug maker’s India unit and vice-president of its operations in South Asia, spoke to Aneesh Phadnis & Abhineet Kumar on the company’s growth strategy in the near future. Edited excerpts: Is the impact of the GST over now? We believe we will come out of the de-stocking situation through a re-stocking. This was a big event and expecting ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?